Skip to content

Intralesional bleomycin in treatment of warts.

A study for efficacy and safety of intralesional bleomycin in common warts including palmo-plantar and periungual warts

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013739
Enrollment
150
Registered
2018-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue Health Condition 2: null- Patients having commen warts including palmo-plantar and periungual warts

Interventions

Intervention1: Bleomycin: Intralesional bleomycin in warts Intervention2: Intralesional bleomycin in warts: Bleomycin in 1mg/ml dilution not excedding 2mg in single sitting will be injected using insu

Sponsors

Dr RPGMC Tanda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients with palmoplantar and periungual warts more than 12 years of age requiring less than 2mg of bleomycin injection

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Children 3. Patients with Reynaudâ??s phenomenon or peripheral vascular disease 4. Patients with immune suppression from any disease or drug therapy 5. Patients with extensive warts requiring more than 2mg bleomycin

Design outcomes

Primary

MeasureTime frame
Clearance of wartsTimepoint: Two injections of Bleomycin will be given two weeks apart and patient will be followed at 4rth and 12th week after the first injection.

Secondary

MeasureTime frame
Complete, partial or incomplete response to therapyTimepoint: Patients will be evaluated at 12 weeks to find out whether there is complete, partial or no response to treatment protocol.

Countries

India

Contacts

Public ContactDr Prabal Kumar
vkm1@rediff.com9418007941

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026